fractures

骨折
  • 文章类型: Journal Article
    三环抗抑郁药可有效控制抑郁症和其他疾病。然而,由于它们的抗胆碱能特性,它们会引起不良反应,这类事件的风险随着年龄的增长而增加。本研究确定并描述了评估三环抗抑郁药使用与不良健康结果之间关联的临床研究(跌倒,骨折,和死亡率)在老年人中。对英语文献的系统搜索,西班牙语,法语是使用电子数据库PubMed进行的,ISIWebofScience,PsycINFO,还有Cochrane.系统评价共纳入18项研究。荟萃分析检查了14项研究,这些研究调查了三环抗抑郁药的使用与跌倒和骨折风险之间的关系(18项研究中有4项关注死亡率,因此被排除在荟萃分析之外)。比值比(OR)为1.40(95%CI=1.27-1.53,p<0.001)。CochranQ检验显著(X2=79.72,p<0.001),表明高度异质性(I2=84.9%)。对报告风险比(HRs)的研究进行了额外的荟萃分析,HR为1.21(95%CI=0.93-1.58,p=0.16)。荟萃回归分析表明,随访年限对所研究的关联有显著影响(p=0.008)。总之,加强我们对老年人抗抑郁药的使用和相关不良事件风险的了解,将有助于确定每种临床情况下最合适的抗抑郁药类型.
    Tricyclic antidepressants are effective for managing depression and other disorders. However, they can cause adverse reactions due to their anticholinergic properties, with the risk of such events increasing with age. This study identifies and describes clinical studies that evaluate associations between the use of tricyclic antidepressants and adverse health outcomes (falls, fractures, and mortality) among older people. A systematic search of the literature in English, Spanish, and French was conducted using the electronic databases PubMed, ISI Web of Science, PsycINFO, and Cochrane. The systematic review included a total of 18 studies. The meta-analysis examined the 14 studies that investigated the association between the use of tricyclic antidepressants and the risk of falls and fractures (4 of the 18 studies focused on mortality and so were excluded from the meta-analysis). The odds ratio (OR) was 1.40 (95 % CI = 1.27-1.53, p < 0.001). The Cochran Q test was significant (X2 = 79.72, p < 0.001), indicating high heterogeneity (I2 = 84.9 %). An additional meta-analysis was conducted on studies reporting hazard ratios (HRs), yielding an HR of 1.21 (95 % CI = 0.93-1.58, p = 0.16). Meta-regression analysis indicated that the years of follow-up could have a significant effect on the association studied (p = 0.008). In conclusion, enhancing our understanding of the use of antidepressants and the associated risk of adverse events in older adults will enable the identification of the most appropriate type of antidepressant for each clinical situation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    牙种植体骨折对长期治疗成功构成重大挑战。本系统综述旨在全面检查影响牙种植体骨折(IFs)的临床因素。此外,解决了选择正确类型的植入物和预防这种并发症的策略。在PubMed进行了系统的搜索,Scopus,和WebofScience数据库。符合条件的研究包括回顾性病例对照,前瞻性队列研究,和临床试验。最初的搜索产生了361篇文章,其中312项被排除在这些评论之外,病例报告,无关紧要,或用英语以外的其他语言写的。这留下了49篇文章,只有6人符合深入审查的资格标准。这些研究,所有回顾性病例对照,检查植入物特性,患者人口统计学,手术和假体变量,生物力学和功能因素,临床和程序变量,并发症和维护问题。使用ROBINS-I工具评估偏倚风险较低。主要研究结果表明,植入物直径和结构阻力之间存在相关性,更广泛的植入物显示骨折风险降低。此外,后部区域,尤其是磨牙和前磨牙,由于咀嚼力的增加,对IFs的敏感性更高。植入物的设计和材料可能会显著影响骨折风险,锥形植入物和螺钉保留假体显示出更高的脆弱性。生物力学过载,尤其是磨牙症患者,成为IFs的主要促成因素。假体类型显著影响骨折发生率,悬臂假体由于应力增加而带来更高的风险。种植体周围骨丢失与IFs密切相关,强调需要细致的术前评估和个性化管理策略。未来的研究应该优先考虑更大的和异质的群体与长期随访和标准化的方法,以提高结果的普遍性和可比性。在受控条件下进行随机对照试验和生物力学研究对于阐明导致IFs的复杂相互作用和制定有效的预防策略也至关重要。此外,整合患者报告的结局可以全面了解IFs对生活质量的影响.
    Dental implant fractures pose a significant challenge to long-term treatment success. This systematic review aims to comprehensively examine the clinical factors influencing dental implant fractures (IFs). Furthermore, strategies to choose the right type of implant and prevent this complication are addressed. A systematic search was conducted across PubMed, Scopus, and Web of Science databases. Eligible studies included retrospective case-control, prospective cohort studies, and clinical trials. The initial search yielded 361 articles, of which 312 were excluded being these reviews, case reports, irrelevant, or written in languages other than English. This left 49 articles, with only 6 meeting the eligibility criteria for an in-depth review. These studies, all retrospective case-control, examine implant characteristics, patient demographics, surgical and prosthetic variables, biomechanical and functional factors, clinical and procedural variables, complications and maintenance issues. The risk of bias was assessed as low using the ROBINS-I tool. Key findings suggest a correlation between implant diameter and structural resistance, with wider implants demonstrating reduced fracture risk. Additionally, posterior regions, especially molars and premolars, exhibit higher susceptibility to IFs due to increased masticatory forces. Implant design and material may considerably influence fracture risk, with conical implants and screw-retained prostheses showing higher vulnerability. Biomechanical overload, particularly in patients with bruxism, emerges as a primary contributing factor to IFs. Prosthesis type significantly influences fracture incidence, with cantilever prostheses posing a higher risk due to increased stress. Peri-implant bone loss is strongly associated with IFs, emphasizing the need for meticulous preoperative assessments and individualized management strategies. Future research should prioritize larger and heterogeneous populations with long-term follow-up and standardized methodologies to enhance the generalizability and comparability of findings. Randomized controlled trials and biomechanical studies under controlled conditions are also essential to elucidate the complex interactions contributing to IFs and developing effective prevention strategies. Additionally, integrating patient-reported outcomes may offer a comprehensive understanding of the impact of IFs on quality of life.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:二肽基肽酶4(DPP-4)在分解各种底物中起关键作用。它也对胰岛素信号通路有影响,导致胰岛素抵抗,并参与炎症过程,如肥胖和2型糖尿病。DPP-4对骨代谢的新作用包括DPP-4活性水平与骨矿物质密度之间的反比关系。伴随着骨折的风险增加。
    方法:DPP-4对骨代谢的影响通过两个轴发生。肠-内分泌-骨轴涉及DPP-4的胃肠底物,包括葡萄糖依赖性促胰岛素多肽(GIP)和胰高血糖素样肽1(GLP-1)和2(GLP-2)。研究表明,超生理剂量的外源性GLP-2对骨吸收有显著的抑制作用,然而,GLP-2影响骨代谢的具体机制尚不清楚.其中,GIP因其在骨形成中的作用而脱颖而出。其他胃肠道DPP-4底物是胰腺肽YY和神经肽Y-两者都与相同的受体结合并且似乎增加骨吸收并减少骨形成。脂肪因子(例如,瘦素和脂联素)受DPP-4调节,可能以旁分泌方式影响骨重塑和能量代谢。胰腺-内分泌-骨轴涉及DPP-4,骨,和能量代谢通过核因子κB受体激活剂配体(RANKL),诱导DPP-4在破骨细胞中的表达,导致GLP-1水平降低和血糖水平升高。DPP-4的抑制剂通过增加内源性GLP-1参与胰腺-内分泌-骨轴。除了它们的血糖效应,DPP-4抑制剂具有降低骨吸收的潜力,增加骨形成,减少骨质疏松和骨折的发生率。尽管如此,关于DPP-4和骨骼之间相互作用的许多问题仍然没有答案,特别是关于DPP-4抑制对老年人骨骼的影响。
    结论:阐明DPP-4对骨骼的复杂相互作用和影响对于正确理解人体调节骨骼稳态和对内部刺激的反应的机制至关重要。这种理解在骨质疏松症等疾病的调查中具有重要意义,其中这些信号通路发生中断。进一步的研究对于揭示DPP-4对骨代谢和能量调节的全面影响至关重要。为针对这些途径的新型治疗干预铺平了道路,尤其是老年人。
    BACKGROUND: Dipeptidyl peptidase 4 (DPP-4) plays a crucial role in breaking down various substrates. It also has effects on the insulin signaling pathway, contributing to insulin resistance, and involvement in inflammatory processes like obesity and type 2 diabetes mellitus. Emerging effects of DPP-4 on bone metabolism include an inverse relationship between DPP-4 activity levels and bone mineral density, along with an increased risk of fractures.
    METHODS: The influence of DPP-4 on bone metabolism occurs through two axes. The entero-endocrine-osseous axis involves gastrointestinal substrates for DPP-4, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptides 1 (GLP-1) and 2 (GLP-2). Studies suggest that supraphysiological doses of exogenous GLP-2 has a significant inhibitory effect on bone resorption, however the specific mechanism by which GLP-2 influences bone metabolism remains unknown. Of these, GIP stands out for its role in bone formation. Other gastrointestinal DPP-4 substrates are pancreatic peptide YY and neuropeptide Y-both bind to the same receptors and appear to increase bone resorption and decrease bone formation. Adipokines (e.g., leptin and adiponectin) are regulated by DPP-4 and may influence bone remodeling and energy metabolism in a paracrine manner. The pancreatic-endocrine-osseous axis involves a potential link between DPP-4, bone, and energy metabolism through the receptor activator of nuclear factor kappa B ligand (RANKL), which induces DPP-4 expression in osteoclasts, leading to decreased GLP-1 levels and increased blood glucose levels. Inhibitors of DPP-4 participate in the pancreatic-endocrine-osseous axis by increasing endogenous GLP-1. In addition to their glycemic effects, DPP-4 inhibitors have the potential to decrease bone resorption, increase bone formation, and reduce the incidence of osteoporosis and fractures. Still, many questions on the interactions between DPP-4 and bone remain unanswered, particularly regarding the effects of DPP-4 inhibition on the skeleton of older individuals.
    CONCLUSIONS: The elucidation of the intricate interactions and impact of DPP-4 on bone is paramount for a proper understanding of the body\'s mechanisms in regulating bone homeostasis and responses to internal stimuli. This understanding bears significant implications in the investigation of conditions like osteoporosis, in which disruptions to these signaling pathways occur. Further research is essential to uncover the full extent of DPP-4\'s effects on bone metabolism and energy regulation, paving the way for novel therapeutic interventions targeting these pathways, particularly in older individuals.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    随着年龄的增长,保持良好的口腔健康对于执行日常任务变得越来越重要。与年龄相关的生理衰退会破坏各种生物系统,对老年牙科造成重大挑战。使用六个不同的电子数据库对文献进行了系统回顾,以调查老年人口腔健康指标与骨密度障碍之间的关系。该研究在PROSPERO(CRD42023403340)上注册为先验协议。60岁的最低年龄是所有原始研究文章的主要纳入标准。两名独立研究人员根据纳入标准评估了19,362条记录的资格,发现12篇文章符合资格要求。口腔健康不良的五个不同指标[牙齿数量,牙周病,一般口腔健康(龋齿患病率和牙科治疗需求),咀嚼功能,和咬合力)]被发现与骨密度障碍(骨质疏松症,骨折,和骨矿物质密度降低),无论采用何种评估工具。牙齿数量与骨折和骨密度降低呈负相关,而牙周病与骨质疏松和骨密度降低呈正相关。咀嚼功能仅与骨质疏松症有关,而一般的口腔健康仅与骨折有关,而咬合力仅与骨矿物质密度有关。与骨矿物质密度障碍相关的结果最常见的口腔健康指标是牙齿数量。目前的发现可能有助于评估每个口腔健康指标对老年人骨矿物质密度障碍发展的贡献。
    As we age, maintaining good oral health becomes increasingly crucial for performing daily tasks. Age-related physiological decline can disrupt various biological systems, causing a significant challenge for geriatric dentistry. A systematic review of the literature using six different electronic databases was conducted to investigate the relationship between oral health indicators and bone mineral density disorders in older adults. The study is registered as a priori protocol on PROSPERO (CRD42023403340). A minimum age of 60 years was the main inclusion criterion for all original research articles. Two independent researchers assessed the eligibility of 19,362 records against the inclusion criteria and found 12 articles fitting the eligibility requirements. Five different indicators of poor oral health [number of teeth, periodontal disease, general oral health (dental caries prevalence and dental treatment needs), masticatory function, and occlusal force)] were found related to three outcomes linked to bone mineral density disorders (osteoporosis, fractures, and decreased bone mineral density), regardless of the adopted assessment tools. The number of teeth was negatively associated with fractures and a decreased bone mineral density, while periodontal disease was positively associated with osteoporosis and a decreased bone mineral density. Masticatory function was associated only with osteoporosis, while general oral health was associated only with fractures and occlusal force only with bone mineral density. The oral health indicator most frequently associated with outcomes linked to bone mineral density disorders was the number of teeth. The present findings could help to assess the contribution of each oral health indicator to the development of bone mineral density disorders in older age.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:临床前和动物研究表明,过量的儿茶酚胺可导致骨矿物质丢失。然而,到目前为止,目前尚无系统综述分析嗜铬细胞瘤/副神经节瘤(PPGL)患者中儿茶酚胺过量对骨代谢的影响.我们进行了这项荟萃分析来解决这一知识差距。
    方法:在电子数据库中搜索评估骨代谢的研究,包括骨矿物质密度(BMD)的评估,定量计算机断层扫描(qCT),骨小梁评分(TBS),或PPGL患者的骨转换标志物。这些标记包括骨吸收的标记,如抗酒石酸酸性磷酸酶5b(TRACP-5b)和I型胶原的交联C端肽(CTx),以及骨形成的标记,例如骨特异性碱性磷酸酶(BSALP)。
    结果:在最初筛选的1614篇文章中,我们分析了在4个不同的PPGL患者队列中发表的符合所有标准的6项研究的数据.PPGL患者的TBS显著降低[平均差(MD)-0.04(95%CI:-0.05--0.03);p<0.00001;I2=0%],较高的血清CTx[MD0.13ng/ml(95%CI:0.08-0.17);p<0.00001;I2=0%],和较高的BS-ALP[MD1.47U/L(95%CI:0.30-2.64);p=0.01;I2=1%]。术后4-7个月TBS显著高于基线[MD0.05(95%CI:0.02-0.07);p<0.0001]。已经记录了术后CTx的减少。
    结论:骨健康恶化是PPGL患者的主要问题。除了为儿茶酚胺过量提供明确的治疗方法之外,监测和治疗骨质疏松对PPGL继发骨质疏松患者至关重要.关于PPGL骨健康结果的长期研究是有必要的。
    BACKGROUND: Preclinical and animal studies have suggested that excess catecholamines can lead to bone mineral loss. However, to date, no systematic review is available that has analyzed the impact of catecholamine excess in the context of pheochromocytoma/paraganglioma (PPGL) on bone metabolism. We conducted this meta-analysis to address this knowledge gap.
    METHODS: Electronic databases were searched for studies evaluating bone metabolism, including assessments of bone mineral density (BMD), quantitative computed tomography (qCT), trabecular bone score (TBS), or bone turnover markers in patients with PPGL. These markers included those of bone resorption, such as tartrate-resistant acid phosphatase 5b (TRACP-5b) and cross-linked C-telopeptide of type I collagen (CTx), as well as markers of bone formation, such as bone-specific alkaline phosphatase (BS ALP).
    RESULTS: Out of the initially screened 1614 articles, data from six studies published in four different patient cohorts with PPGL that met all criteria were analysed. Individuals with PPGL had significantly lower TBS [Mean Difference (MD) -0.04 (95% CI: -0.05--0.03); p < 0.00001; I2 = 0%], higher serum CTx [MD 0.13 ng/ml (95% CI: 0.08-0.17); p < 0.00001; I2 = 0%], and higher BS-ALP [MD 1.47 U/L (95% CI: 0.30-2.64); p = 0.01; I2 = 1%]. TBS at 4-7 months post-surgery was significantly higher compared to baseline [MD 0.05 (95% CI: 0.02-0.07); p < 0.0001]. A decrease in CTx has been documented post-surgery.
    CONCLUSIONS: Bone health deterioration is a major concern in patients with PPGL. In addition to providing a definitive cure for catecholamine excess, monitoring and treating osteoporosis is essential for individuals with secondary osteoporosis due to PPGL. Long-term studies on bone health outcomes in PPGL are warranted.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    肾上腺腺瘤/偶发瘤伴轻度自主皮质醇分泌(MACS)/亚临床皮质醇增多症(SH)常与代谢综合征相关,糖皮质激素引起的骨质疏松和骨折。在这样的背景下,本系统综述和荟萃分析旨在整理现有证据,并提供MACS/SH在骨折方面对骨骼健康的影响的总结。骨质疏松/骨质减少,微体系结构,和骨周转。PubMed/MEDLINE,Embase,和WebofScience数据库被系统地搜索了报告骨折患病率的观察性研究,骨质疏松症/骨质减少或骨微结构/骨转换标志物(BTMs)的数据。在文献检索之后,纳入16项观察性研究。任何骨折(椎骨和非椎骨)的合并患病率,MACS/SH患者的椎体骨折和骨质疏松/骨质减少为43%[95%置信区间(CI):23%,62%],45%(95%CI:22%,68%)和50%(95%CI:33%,66%),分别。关于元回归,年龄,性别,24小时尿游离皮质醇和硫酸脱氢表雄酮不能预测骨折风险。任何骨折的可能性[优势比(OR)1.61;95%CI:1.18,2.20;p=0.0026],在肾上腺腺瘤和MACS/SH中,椎体骨折(OR2.10;95%CI:1.28,3.45;p=0.0035)和骨质疏松/骨质减少(OR1.46;95%CI:1.15,1.85;p=0.0018)显著高于无功能性肾上腺腺瘤.患有MACS/SH的受试者腰椎的骨矿物质密度(BMD)显着降低[平均差(MD)-0.07gm/cm2;95%CI:-0.11,-0.03;p=0.0004)和股骨颈(MD-0.05gm/cm2;95%CI:-0.08,-0.02;p=0.0045)。有限的数据显示BTMs没有显着差异。在任何骨折的合并患病率中观察到发表偏倚,椎体骨折和股骨颈BMD合并MD。最后,与无功能性肾上腺腺瘤相比,患有肾上腺腺瘤/偶发瘤和MACS/SH的患者发生骨折和骨质疏松/骨质减少的可能性高1.5~2倍,因此应常规筛查骨病.然而,考虑到研究的样本量和发表偏倚的证据,需要更大规模和高质量的研究(CRD42023471045)。
    轻度自主皮质醇分泌(MACS),通常也被称为亚临床皮质醇增多症(SH),通常与潜在的肾上腺偶发瘤(AI)有关,腹部成像时偶然发现的肾上腺肿块。尽管缺乏明显的皮质醇过量的迹象,患有MACS/SH的受试者通常具有代谢综合征的特征,骨质疏松症和骨折。本系统综述和荟萃分析显示,任何骨折(椎骨和非椎骨)的合并患病率,MACS/SH的椎骨骨折和骨质疏松/骨质减少占43%,45%和50%,分别。与非功能性肾上腺腺瘤相比,患有肾上腺腺瘤/偶发瘤和MACS/SH的人发生骨折和骨质疏松症/骨质减少的可能性高1.5至2倍。此外,MACS/SH患者腰椎和股骨颈的骨矿物质密度(BMD)明显低于无功能者.因此,必须评估所有MACS/SH受试者的骨骼健康状况。
    Adrenal adenomas/incidentalomas with mild autonomous cortisol secretion (MACS)/subclinical hypercortisolism (SH) are often associated with metabolic syndrome, glucocorticoid-induced osteoporosis, and fractures. In this background, the present systematic review and meta-analysis aimed to collate the available evidence and provide a summary of the effect of MACS/SH on bone health in terms of fractures, osteoporosis/osteopenia, microarchitecture, and bone turnover. PubMed/MEDLINE, Embase, and Web of Science databases were systematically searched for observational studies reporting prevalence of fractures, osteoporosis/osteopenia or data on bone microarchitecture/bone turnover markers (BTMs). Following literature search, 16 observational studies were included. Pooled prevalence of any fractures (vertebral and non-vertebral), vertebral fractures, and osteoporosis/osteopenia in MACS/SH were 43% [95% confidence intervals (CI): 23%, 62%], 45% (95% CI: 22%, 68%) and 50% (95% CI: 33%, 66%), respectively. On meta-regression, age, sex, 24-hour urinary free cortisol, and dehydroepiandrosterone-sulfate did not predict fracture risk. The likelihood of any fractures [odds ratio (OR) 1.61; 95% CI: 1.18, 2.20; P = 0.0026], vertebral fractures (OR 2.10; 95% CI: 1.28, 3.45; P = 0.0035), and osteoporosis/osteopenia (OR 1.46; 95% CI: 1.15, 1.85; P = 0.0018) was significantly higher in adrenal adenomas and MACS/SH than non-functional adrenal adenomas. Subjects with MACS/SH had significantly lower bone mineral density (BMD) at lumbar spine [mean difference (MD) -0.07 g/cm2; 95% CI: -0.11, -0.03; P = 0.0004) and femoral neck (MD -0.05 g/cm2; 95% CI: -0.08, -0.02; P = 0.0045) than their non-functional counterparts. Limited data showed no significant difference in BTMs. Publication bias was observed in the pooled prevalence of any fractures, vertebral fractures and pooled MD of femoral neck BMD. To conclude, people with adrenal adenomas/incidentalomas and MACS/SH are at a 1.5- to 2-fold higher likelihood of fractures and osteoporosis/osteopenia compared to non-functional adrenal adenomas and should routinely be screened for bone disease. Nevertheless, considering the modest sample size of studies and evidence of publication bias, larger and high-quality studies are required (CRD42023471045).
    Mild autonomous cortisol secretion (MACS), often also referred to as subclinical hypercortisolism (SH), is usually associated with an underlying adrenal incidentaloma (AI), an adrenal mass incidentally found during abdomen imaging. Although signs of overt cortisol excess are lacking, subjects with MACS/SH often have features of metabolic syndrome, osteoporosis and fractures. The present systematic review and meta-analysis showed that the pooled prevalence of any fractures (vertebral and non–vertebral), vertebral fractures, and osteoporosis/osteopenia in MACS/SH were 43%, 45%, and 50%, respectively. People with adrenal adenomas/incidentalomas and MACS/SH are at a 1.5- to 2-fold higher likelihood of fractures and osteoporosis/osteopenia compared to non–functional adrenal adenomas. Besides, subjects with MACS/SH had significantly lower bone mineral density at lumbar spine and femoral neck than their non–functional counterparts. It is thus imperative to assess bone health in all subjects with MACS/SH.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    本文综述了实体器官移植诱导的骨质疏松症,一个关键但经常被忽视的问题,强调其在移植后护理中的重要性。初始部分提供了对移植骨质疏松症的患病率和多因素发病机制的全面了解。包括移植后健康状况恶化等因素,荷尔蒙的变化,以及免疫抑制药物的影响。此外,该审查致力于移植骨质疏松症中器官特异性的考虑,对肾脏进行单独分析,肝脏,心,和肺移植。每个部分都阐明了与每种器官类型相关的移植骨质疏松症的独特挑战和管理策略。强调器官特异性方法的必要性,以充分了解移植骨质疏松症的各种表现和影响。这篇综述强调了这一主题在移植医学中的重要性,旨在提高临床医生和研究人员的认识和知识。通过全面检查移植骨质疏松症,这项研究有助于制定改进的管理和护理策略,最终改善了这一弱势群体的患者预后。这篇详细的综述是参与移植受者复杂多学科护理的人员的重要资源。
    This review article investigates solid organ transplantation-induced osteoporosis, a critical yet often overlooked issue, emphasizing its significance in post-transplant care. The initial sections provide a comprehensive understanding of the prevalence and multifactorial pathogenesis of transplantation osteoporosis, including factors such as deteriorating post-transplantation health, hormonal changes, and the impact of immunosuppressive medications. Furthermore, the review is dedicated to organ-specific considerations in transplantation osteoporosis, with separate analyses for kidney, liver, heart, and lung transplantations. Each section elucidates the unique challenges and management strategies pertinent to transplantation osteoporosis in relation to each organ type, highlighting the necessity of an organ-specific approach to fully understand the diverse manifestations and implications of transplantation osteoporosis. This review underscores the importance of this topic in transplant medicine, aiming to enhance awareness and knowledge among clinicians and researchers. By comprehensively examining transplantation osteoporosis, this study contributes to the development of improved management and care strategies, ultimately leading to improved patient outcomes in this vulnerable group. This detailed review serves as an essential resource for those involved in the complex multidisciplinary care of transplant recipients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    骨折愈合对骨科构成了重大挑战。骨的成功再生由机械稳定性和有利的生物微环境提供。本系统评价旨在探讨直系生物制剂在成人长骨无菌性延迟愈合和不愈合中的临床应用。
    根据系统评价和荟萃分析(PRISMA)指南的首选报告项目进行系统评价。探索了三个数据库,没有日期限制,使用与直视生物学、延迟联合和不联合相关的关键词。符合条件的研究包括英语的人体临床研究,有可用的全文,检查直系生物制剂,如富血小板血浆(PRP),间充质干细胞(MSCs),和骨形态发生蛋白(BMPs)用于治疗成人无菌性延迟愈合和不愈合。动物研究,体外研究,以及对先天性缺陷导致的不结合的研究,肿瘤或感染被排除。
    最初的搜索确定了9417项研究,其中20人最终被纳入审查。这些研究涉及493名受不愈合影响的患者和256名受延迟愈合影响的患者,平均年龄分别为40.62岁和41.7岁。非工会的平均随访期为15.55个月,延迟工会的平均随访期为8.07个月。PRP是最常用的矫正生物学,结果是通过联合时间来评估的,功能分数,和临床检查。结果表明,直向生物学,尤其是PRP,与没有生物学因素的外科手术相比,倾向于产生更好的结果。
    这项系统评价表明,直系生物学,如PRP,BMPs,和MSC,可以有效和安全地管理延迟愈合和不愈合骨折。这些生物治疗有可能提高结合率,减少愈合时间,并提高不愈合骨折患者的功能预后。进一步的研究对于完善治疗方案并确定针对特定患者人群和骨折类型的最合适的骨科生物至关重要。
    UNASSIGNED: Fracture healing poses a significant challenge in orthopedics. Successful regeneration of bone is provided by mechanical stability and a favorable biological microenvironment. This systematic review aims to explore the clinical application of orthobiologics in treating aseptic delayed union and non-union of long bones in adults.
    UNASSIGNED: A systematic review was conducted following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. Three databases were explored, with no date restrictions, using keywords related to orthobiologics and delayed union and non-union. Eligible studies included human clinical studies in English, with available full texts, examining orthobiologics such as platelet-rich plasma (PRP), mesenchymal stem cells (MSCs), and bone morphogenetic protein (BMPs) for treating aseptic delayed unions and non-unions in adults. Animal studies, in vitro research, and studies on non-unions due to congenital defects, tumors or infections were excluded.
    UNASSIGNED: The initial search identified 9417 studies, with 20 ultimately included in the review. These studies involved 493 patients affected by non-union and 256 patients affected by delayed union, with an average age respectively of 40.62 years and 41.7 years. The mean follow-up period was 15.55 months for non-unions and 8.07 months for delayed unions. PRP was the most used orthobiologic, and outcomes were evaluated through time to union, functional scores, and clinical examinations. The results indicated that orthobiologics, especially PRP, tended to yield better outcomes compared to surgical procedures without biological factors.
    UNASSIGNED: This systematic review suggests that orthobiologics, such as PRP, BMPs, and MSCs, can be effective and safe in the management of delayed union and non-union fractures. These biological treatments have the potential to improve union rates, reduce healing times, and enhance functional outcomes in patients with non-union fractures. Further research is essential to refine treatment protocols and determine the most suitable orthobiologic for specific patient populations and fracture types.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    骨质疏松症是指一组相关的罕见骨疾病,其特征是由于破骨细胞的骨吸收受损而导致的高骨量。尽管骨量很大,骨骼强度受损,骨折风险很高,特别是在长骨中。石骨症按遗传模式经典分类为常染色体隐性形式(ARO),在生命的最初几年就被诊断出严重的疾病,中间形式和常染色体显性(ADO)形式;后者具有不同的临床严重程度,通常在青春期或成年期被诊断。随后,AD形式被证明是编码ClC-7氯化物通道的基因CLCN7突变的结果)。传统上,石骨症的诊断仅根据X线片外观,但是最近的分子和遗传进展使石骨症亚型的分类具有更高的保真度。在更严重的ARO形式中(例如,恶性婴儿石骨症MIOP)的典型临床特征具有严重的后果,通常会导致儿童早期死亡。ADO的主要并发症是非典型骨折,修复延迟或失败以及骨科管理方面的挑战。骨髓衰竭,牙脓肿,由于缺乏意识和专业知识,耳聋和视力丧失往往被低估和忽视。因此,成人石骨症患者的治疗需要多学科的方法,最好是在专业中心.除了某些婴儿形式的造血干细胞移植,石骨症患者的治疗,尚未标准化,仍然支持。需要进一步的临床研究来提高我们对自然史的认识,石骨症的最佳治疗和对患者生活的影响。
    Osteopetrosis refers to a group of related rare bone diseases characterized by a high bone mass due to impaired bone resorption by osteoclasts. Despite the high bone mass, skeletal strength is compromised and the risk of fracture is high, particularly in the long bones. Osteopetrosis was classically categorized by inheritance pattern into autosomal recessive forms (ARO), which are severe and diagnosed within the first years of life, an intermediate form and an autosomal dominant (ADO) form; the latter with variable clinical severity and typically diagnosed during adolescence or in young adulthood. Subsequently, the AD form was shown to be a result of mutations in the gene CLCN7 encoding for the ClC-7 chloride channel). Traditionally, the diagnosis of osteopetrosis was made on radiograph appearance alone, but recent molecular and genetic advances have enabled a greater fidelity in classification of osteopetrosis subtypes. In the more severe ARO forms (e.g., malignant infantile osteopetrosis MIOP) typical clinical features have severe consequences and often result in death in early childhood. Major complications of ADO are atypical fractures with delay or failure of repair and challenge in orthopedic management. Bone marrow failure, dental abscess, deafness and visual loss are often underestimated and neglected in relation with lack of awareness and expertise. Accordingly, the care of adult patients with osteopetrosis requires a multidisciplinary approach ideally in specialized centers. Apart from hematopoietic stem cell transplantation in certain infantile forms, the treatment of patients with osteopetrosis, has not been standardized and remains supportive. Further clinical studies are needed to improve our knowledge of the natural history, optimum management and impact of osteopetrosis on the lives of patients living with the disorder.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:血管舒缩症状(VMS)对绝经后生活质量有不利影响。然而,它们与骨骼健康的关系尚未阐明。本研究旨在系统回顾和荟萃分析绝经前后女性VMS与骨折风险和骨密度(BMD)相关的证据。
    方法:在PubMed,Scopus和Cochrane数据库,直到2023年8月31日。骨折,评估了低BMD(骨质疏松症/骨质减少)以及腰椎(LS)和股骨颈(FN)BMD的平均变化。结果以比值比(OR)和平均差(MD)表示,分别,95%置信区间(95%CI)。I2指数量化了异质性。
    结果:20项研究纳入定性分析,12项纳入定量分析(n=49,659)。有和没有VMS的女性之间的骨折没有差异(n=5,OR1.04,95%CI0.93-1.16,I216%)。然而,VMS与低骨密度相关(n=5,OR1.54,95%CI1.42-1.67,I20%)。对于LS(MD-0.019g/cm2,95%CI-0.03至-0.008,I285.2%),但不适用于FNBMD(MD-0.010g/cm2,95%CI-0.021至0.001,I278.2%)。这些结果与VMS严重程度无关,年龄和学习设计。当分析仅限于排除更年期激素治疗使用的研究时,与BMD的相关性仍然显著.
    结论:VMS的存在与绝经后妇女的低骨密度有关,虽然它似乎不会增加骨折风险。
    OBJECTIVE: Vasomotor symptoms (VMS) adversely affect postmenopausal quality of life. However, their association with bone health has not been elucidated. This study aimed to systematically review and meta-analyze the evidence regarding the association of VMS with fracture risk and bone mineral density (BMD) in peri- and postmenopausal women.
    METHODS: A literature search was conducted in PubMed, Scopus and Cochrane databases until 31 August 2023. Fracture, low BMD (osteoporosis/osteopenia) and mean change in lumbar spine (LS) and femoral neck (FN) BMD were assessed. The results are presented as odds ratio (OR) and mean difference (MD), respectively, with a 95% confidence interval (95% CI). The I2 index quantified heterogeneity.
    RESULTS: Twenty studies were included in the qualitative and 12 in the quantitative analysis (n=49,659). No difference in fractures between women with and without VMS was found (n=5, OR 1.04, 95% CI 0.93-1.16, I2 16%). However, VMS were associated with low BMD (n=5, OR 1.54, 95% CI 1.42-1.67, I2 0%). This difference was evident for LS (MD -0.019 g/cm2, 95% CI -0.03 to -0.008, I2 85.2%), but not for FN BMD (MD -0.010 g/cm2, 95% CI -0.021 to 0.001, I2 78.2%). These results were independent of VMS severity, age and study design. When the analysis was confined to studies that excluded menopausal hormone therapy use, the association with BMD remained significant.
    CONCLUSIONS: The presence of VMS is associated with low BMD in postmenopausal women, although it does not seem to increase fracture risk.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号